Skip to main navigation

About Us
Our Science
Our Portfolio
Investors & Media
Careers
- Join Us
- Current Openings
Contact

News Releases

Year

Jun 30, 2022

Omega Therapeutics Presents New Preclinical Data Supporting the First Epigenomic Controller, OTX-2002, as a Potential Therapeutic Approach in Hepatocellular Carcinoma at the ESMO 2022 World Congress on Gastrointestinal Cancer

Jun 23, 2022

Omega Therapeutics to Present New Preclinical Data for the First Epigenomic Controller, OTX-2002, for Hepatocellular Carcinoma at the European Society of Medical Oncology's 2022 World Congress on Gastrointestinal Cancer

Jun 15, 2022

Omega Therapeutics Announces Submission of Investigational New Drug Application for OTX-2002, an Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma

Jun 02, 2022

Omega Therapeutics to Participate in the Jefferies Healthcare Conference and Goldman Sachs 43rd Annual Global Healthcare Conference in June 2022

May 04, 2022

Omega Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

May 03, 2022

Omega Therapeutics to Unveil Preclinical Data on Epigenomic Programming of MYC with Epigenomic Controllers as a Promising Therapeutic Approach in Non-Small Cell Lung Cancer at the 25th Annual ASGCT Meeting

Apr 29, 2022

Omega Therapeutics Announces Appointment of Joshua Reed as Chief Financial Officer

Apr 08, 2022

Omega Therapeutics Presents Preclinical Data on OTX-2002, First-in-Class Epigenomic Controller, as Potential Treatment for Hepatocellular Carcinoma at the AACR Annual Meeting 2022

Mar 30, 2022

Omega Therapeutics Strengthens Team With Key Management Appointments To Support Its Growth

Mar 10, 2022

Omega Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Outlines Key Corporate Objectives for 2022

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 12

Site - Nav - Investors & Media

Corporate Profile
News & Events
- News Releases
- Events & Presentations
Stock Information
Corporate Governance
Financials & Filings
- SEC Filings
Investor Resources

Presentation

Omega Therapeutics Corporate Overview cover 2022

Corporate Presentation – June 2022 2.5 MB

Investor & Media Contact

Argot Partners
212-600-1902
ArgotOmega@argotpartners.com

Site - Investor Tools

Print Page

Email Alerts

RSS Feeds

Contact IR

Search

Home
About Us
Our Science
Our Portfolio
Investors & Media
Careers
Contact Us

20 Acorn Park Drive
Cambridge, MA 02140

ArgotOmega@argotpartners.com

© Omega Therapeutics, Inc. 2022 All Rights Reserved.
All other trademarks referenced herein are properties of their respective owners.

Terms of use

Privacy Policy